Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

New Study: 340B Entities Not Using the Program as Intended

lab_tech02

A new analysis released by Avalere Health and funded by the Alliance for Integrity and Reform of 340B (AIR 340B) found hospitals participating in the 340B drug pricing program were more likely to acquire independent physician practices than non-340B hospitals. This study looks beyond past research on hospital acquisitions, which largely focused on the higher costs associated with the acquisition of physician practices, to the likelihood of acquisitions among 340B and non-340B entities. This research provides Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Time: How to Breathe New Life Into America’s Health-Care System

21st Century Cures Act

Last week, Rep. Fred Upton (R-MI) published an op-ed – How to Breathe New Life Into America’s Health-Care System – in Time Magazine on the potential of the 21st Century Cures Act to ‘help modernize the health-care innovation infrastructure, incorporate a patient perspective into the drug and device approval process, support advances in personalized medicine, streamline clinical trials, and provide more resources to support cutting-edge research and help young scientists.’ Rep. Upton points out that there are Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

John Lechleiter Forbes Op-Ed: Debunking the Five Big Myths About ‘Big Pharma’

lab_tech02

This week, Eli Lilly and Company President, Chairman and CEO John Lechleiter refutes five big myths about big pharma in this Forbes opinion piece. He points to these five biggest industry myths as ‘routinely poisoning debates, obscuring genuine problems, and distorting policy recommendations on health care.’ In short (excerpts): Myth #1 Pharmaceutical companies exaggerate the costs of developing new medicines to justify high prices. In fact: The research and development (R&D) expenditures of this industry Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Applauds Energy and Commerce Health Subcommittee for Approving 21st Century Cures Act

21st Century Cures Act

Today, the Biotechnology Industry Organization (BIO) praises the Energy and Commerce Health Subcommittee for approving and forwarding to the full Committee the 21st Century Cures Act. We applaud the Energy and Commerce Committee for recognizing the critical link between research, development, and reimbursement. We look forward to continuing to work with Chairman Fred Upton (R-MI), Congresswoman Diana DeGette (D-CO), and members of the Energy and Commerce Committee to help expedite the delivery of the next Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Tick Size Pilot Program: A Few Pennies Make a Big Difference

72263479

Earlier this week, the Securities and Exchange Commission (SEC) approved a tick size pilot program that will begin next year. We issued this statement, praising the SEC for finalizing this program, which could improve liquidity and enhance capital formation for emerging biotech companies. Under current SEC rules, all securities on the public market are priced in $0.01 increments known as “tick sizes.” The switch to the standard tick size of a penny was enacted in 2000 Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,